Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

ProMetic Life Sciences expands PBI-1402 program to include cancer-related anemia

Sep. 14, 2007

Positive results for Regeneron's proof-of-concept study of rilonacept for gout / News in Context

Sep. 14, 2007

EDSMB encourages continuation of phase III trial with Arena's lorcaserin

Sep. 13, 2007

Novel therapeutic options for obesity and metabolic diseases described in recent patents

Sep. 13, 2007

Lilly launches Cialis for erectile dysfunction in Japan

Sep. 12, 2007

OSI Prosidion reports results from metformin and PSN-9301 interaction study

Sep. 12, 2007

Recent Abbott patents describe new ACC inhibitors

Sep. 12, 2007

Pharmacokinetics of GSK-221149A studied to prepare for clinical trial

Sep. 12, 2007

AtheroGenics announces new data on AGI-1067 in diabetes

Sep. 10, 2007

Update on Alba Therapeutics' AT-1001 IND for type 1 diabetes

Sep. 10, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...